Drugs / UltratraceTM Iobenguane I 131
UltratraceTM Iobenguane I 131
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00659984 | Jun 2008 → Aug 2010 | neuroblastoma | Molecular Insight Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UltratraceTM Iobenguane I 131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00659984 ↗ |
| Modality | Other / unclassified | “Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry radiation directly to tumor cells and not harm normal cells.” NCT00659984 ↗ |
| Route | Intravenous | “The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30...” NCT00659984 ↗ |